- Q1 2024 IMCD NV Earnings Call TranscriptApr 26, 2024€146.75 (-1.68%)Earnings
- Q3 2023 IMCD NV Earnings Call TranscriptNov 10, 2023€125.55 (+4.19%)Earnings
- Q2 2023 IMCD NV Earnings Call TranscriptAug 04, 2023€122.95 (-5.93%)Earnings
- Q1 2023 IMCD NV Earnings Call TranscriptApr 26, 2023€137.7 (-4.94%)Earnings
- Q4 2022 IMCD NV Earnings Call TranscriptFeb 24, 2023€141.5 (-3.74%)Earnings
- Q3 2022 IMCD NV Earnings Call TranscriptNov 10, 2022€139.85 (+5.27%)Earnings
- Q2 2022 IMCD NV Earnings Call TranscriptAug 04, 2022€154.1 (+1.58%)Earnings
- Q1 2022 IMCD NV Earnings Call TranscriptApr 29, 2022€153.25 (-0.87%)Earnings
- Q4 2021 IMCD NV Earnings Call TranscriptFeb 25, 2022€139.45 (+1.12%)Earnings
- Q3 2021 IMCD NV Earnings Call TranscriptNov 09, 2021€195.35 (-0.18%)Earnings
- Q2 2021 IMCD NV Earnings Call TranscriptAug 04, 2021€161.55 (+10.35%)Earnings
- Q1 2021 IMCD NV Earnings Call TranscriptApr 29, 2021€121.7 (-0.49%)Earnings
- Full Year 2020 IMCD NV Earnings Call TranscriptFeb 26, 2021€101.85 (-0.68%)Earnings
- Nine Months 2020 IMCD NV Earnings Call TranscriptNov 11, 2020€106.05 (+3.31%)Earnings
- IMCD N.V., Signet Excipients Private Limited - M&A Call TranscriptSep 15, 2020
- Half Year 2020 IMCD NV Earnings Call TranscriptAug 18, 2020€89.56 (-0.42%)Earnings
- Q1 2020 IMCD NV Trading Update Call TranscriptApr 20, 2020
- Full Year 2019 IMCD NV Earnings Call TranscriptFeb 27, 2020€75.95 (-0.20%)Earnings
- Nine Months 2019 IMCD NV Earnings Call TranscriptNov 12, 2019€72.75 (+1.11%)Earnings
- Half Year 2019 IMCD NV Earnings Call TranscriptAug 16, 2019€62.25 (-14.67%)Earnings
- Q1 2019 IMCD NV Earnings Call TranscriptMay 08, 2019€71.35 (+2.74%)Earnings
- Full Year 2018 IMCD NV Earnings Call TranscriptMar 01, 2019€67.4 (-2.18%)Earnings
IMCD N.V., Signet Excipients Private Limited - M&A Call Transcript
Good evening, ladies and gentlemen. Thank you for holding, and welcome to the analyst call of IMCD N.V. (Operator Instructions)
I would now like to hand the call over to Mr. Pieter van Slikke, CEO. Go ahead, please, sir.
Good night, everybody. I'm sitting here with Hans Kooijmans. In front of you, I guess you have the IMCD analyst presentation regarding the acquisition of Signet. I don't want to take you through the whole presentation, but we'll give you some headlines about the strategy and the rationale of this acquisition.
As you know, our business group pharma is a very strong part of IMCD, and we are in many parts of the world present in the distribution of pharmaceutical excipients, products that are used in tableting and all kinds of creams and gels. Our supplier base is mostly companies based in the U.S., in Japan, in Europe, and we have a lot of formulation expertise in this field.
Now our strategy has been to globalize this business as much as
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)